Author: Diana

Combination treatment with the novel adoptive Natural Killer-Like T (NK-T) cell therapy CRX100 and a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in a small cohort of patients with recurrent, platinum-resistant ovarian cancer, according to data from a phase 1 trial (NCT04282044) presented at the 2024 SGO...

19 March, 2024

Mahmoud Mahmoudian, Ph.D.,FRSC, Joins BioEclipse Board; Biopharmaceutical Industry Veteran with Proven Track Record in R&D, Venture Investments, and Business Development Stephen Ghiglieri, Managing Director at Danforth Advisors, to Serve as Interim CFO   MOUNTAIN VIEW, Calif., Jan. 26, 2022 /PRNewswire/ --  BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing...

26 January, 2022

Best StartUp - This article showcases our top picks for the best San Francisco based Therapeutics companies. These startups and companies are taking a variety of approaches to innovating the Therapeutics industry, but are all exceptional companies well worth a follow. We tried to pick companies across the size spectrum from cutting...

07 January, 2022

StartUp Insights - Global Startup Heat Map highlights 5 Top Startups tackling Ovarian Cancer out of 140   The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2.093.000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies &...

04 January, 2022